What is CardioSignal?
CardioSignal is at the forefront of digital health innovation, developing sophisticated digital technologies and software-as-medical-devices. The company's core offering is a groundbreaking technology designed for the early detection of major heart diseases. Uniquely, CardioSignal's platform achieves high accuracy using a single clinical modality, eliminating the need for specialized medical equipment and thereby democratizing access to critical cardiac diagnostics. This advancement positions CardioSignal as a pivotal player in preventative healthcare and remote patient monitoring.
How much funding has CardioSignal raised?
CardioSignal has raised a total of $10M across 1 funding round:
Series A
$10M
Series A (2024): $10M with participation from Maki.vc and DigiTx Partners
Key Investors in CardioSignal
Maki.vc
Maki.vc is an early-stage European venture capital firm specializing in deep tech and brand-driven startups, focusing on pre-seed and seed stages. They support entrepreneurs with audacious ideas and emphasize ESG practices for long-term sustainability.
DigiTx Partners
DigiTx Partners is a venture capital firm focused on early-stage digital health companies, investing in innovative founders leveraging technology and data for personalized medicine and improved patient outcomes.
What's next for CardioSignal?
The substantial enterprise-level backing signifies CardioSignal's transition into a scaling phase, likely focused on expanding its market reach, further refining its AI-driven diagnostic algorithms, and forging strategic partnerships within the healthcare ecosystem. This capital injection is expected to accelerate product development, enhance regulatory approvals, and bolster commercialization efforts, solidifying CardioSignal's position as a leader in digital cardiology and early disease detection.
See full CardioSignal company page
